Pricing Log in Create free account
Sunday 11 October 2026 Export all MRK data to Excel Powerpack

Merck & Co., Inc.

MRK Healthcare Drug Manufacturers General

Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024. In the quarter to June 2026, revenue grew 5.07%, EPS fell 130.7%, free cash flow grew 77.0% and total debt rose 50.4%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for five.

145.60 3.22 +2.26%
Market cap
$351.3B
P/E
116×
Fwd P/E
53.9×
Dividend yield
2.34%
F-score
4/9
Altman Z
3.77
Beneish M
−2.27
Dividend safety
74/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Merck & Co., Inc. 10-K filed Feb 24, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 4:15 PM ET · Document on sec.gov · Filing index

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 1A, Risk Factors, against the 10-K filed Feb 25, 2025: 10 added · 3 removed · 60 modified; 1 with only figures updated

73 more changes in this Item, word by word, in Powerpack.

Powerpack